AbCellera Biologics (ABCL) closed out FY 2025 with Q4 revenue of US$44.9 million and a basic EPS loss of US$0.03, alongside trailing 12 month revenue of US$75.1 million and a full year basic EPS loss of US$0.49, providing a snapshot of a business still investing heavily ahead of profitability. Over the past few quarters, the company reported revenue of US$4.2 million in Q1 2025, US$17.1 million in Q2, US$9.0 million in Q3 and US$44.9 million in Q4, while quarterly EPS losses moved from US$0.15 to US$0.12, US$0.19 and then US$0.03. The market is therefore likely to focus on how these trends affect margins and the development of a credible path out of sustained losses.

See our full analysis for AbCellera Biologics.

With the latest numbers now available, the next step is to see how this earnings profile compares with widely shared narratives about AbCellera, and where those storylines might need to be revised.

Losses remain heavy at US$146 million for the year

• Over the trailing 12 months, AbCellera reported total revenue of US$75.1 million and a net loss of US$146.4 million, which means the business is still spending far more than it brings in from operations.
• Bears point to these ongoing losses as a key concern, and the latest numbers give them plenty to work with:
  • Quarterly net loss was US$8.9 million in Q4 2025 versus losses of US$34.7 million to US$57.1 million in the prior three quarters, so the full year still adds up to a very large US$146.4 million loss on a trailing basis.
  • Analysts also expect earnings to fall by an average of 8.7% per year over the next three years, with the company forecast to remain unprofitable, which aligns with the cautious view that profitability is not close based on current trends.

AbCellera’s latest figures give plenty of fuel for skeptics who focus on the size and persistence of losses, so if you want to see how bearish investors frame this story around the same numbers, check out the detailed bear case: 🐻 AbCellera Biologics Bear Case

Revenue growth near 10% but pipeline doing the heavy lifting

• On a trailing basis, revenue has grown around 10.1% per year to US$75.1 million, while the number of products in Phase I trials moved from 8 in Q3 2024 to 11 by Q3 2025, so more of the effort is now tied up in early clinical programs rather than near term fees.
• Bulls argue that this shift toward a richer pipeline could eventually justify the current investment phase, and the data gives some support to that angle:
  • There are 11 Phase I products in both Q2 and Q3 2025, up from 8 in Q3 2024, which matches the bullish view that AbCellera is ramping its clinical presence and internal programs.
  • Bullish investors also point out that 18 molecules have reached the clinic through partners, and they see that breadth as a way to turn today’s modest 10.1% revenue growth into higher downstream milestone and royalty income if even a fraction of those assets succeed.

If you are curious how optimistic investors connect this growing pipeline to future upside, the full bull case walks through that story in detail: 🐂 AbCellera Biologics Bull Case

Premium 12.7x P/S keeps execution risk front and center

• With a P/S of 12.7x versus around 4.1x for peers and 2.8x for the wider US life sciences industry, AbCellera’s valuation sits at a clear premium even though trailing revenue growth is roughly in line with the broader US market and the company is still loss making.
• Critics highlight that combination of high multiple and weak earnings as a central risk, and the supplied figures line up with that argument:
  • Net losses have grown at an annualized rate of 59.5% over the past five years, yet the stock still trades at more than 3x the peer group P/S and more than 4x the broader industry multiple.
  • Analysts’ consensus price target of US$9.17 sits well above the current share price of US$3.19, but that target assumes earnings of US$17.5 million by around 2028 and implies a P/E multiple above 200x on those future earnings, which leaves little room for disappointment if that earnings path does not play out.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for AbCellera Biologics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given all this, do you feel the story here is more exciting or concerning? Take a moment to look through the numbers yourself and decide where you stand, then check the 3 important warning signs to see which issues others are watching closely.

See What Else Is Out There

AbCellera is still posting heavy annual losses alongside a premium 12.7x P/S multiple, which keeps execution risk and valuation pressure firmly in focus.

If you want ideas where pricing looks less demanding and financial profiles may feel more comfortable, check out 53 high quality undervalued stocks and see how they compare to this story today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.